Celyad SA ,a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced the launch of its corporate rebranding, including changing its name to Celyad Oncology.
Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that it has acquired Baliopharm AG, a...
Bayer HealthCare has sold its molecular imaging business including world rights of florbetaben to Piramal Imaging SA a subsidiary of...
ObsEva SA announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Yselty (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age.
The FDA has on 20 March 2013 approved Dotarem (gadoterate meglumine) from Guerbet SA, for use in Magnetic Resonance Imaging...
Chugai Pharmaceutical announced new results from the phase III study of SA 237 (satralizumab) SAkuraSky Study (NCT02028884) for the treatment...
AC Immune SA announced that its partner Genentech, a member of Roche group, has decided to start a second Phase...
EDAP TMS SA a global leader in therapeutic ultrasound, announced that it has received 510(k) clearance from the FDA for...
Boston Scientific Corporation has announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused...
Roche presented today full pivotal Phase III study results for SA 237 (satralizumab) as a monotherapy for neuromyelitis optica spectrum...